Research programme: cancer therapeutics - Nektar Therapeutics

Drug Profile

Research programme: cancer therapeutics - Nektar Therapeutics

Alternative Names: NKTR-218; NKTR-255

Latest Information Update: 16 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nektar Therapeutics
  • Class Antineoplastics; Immunotherapies; Interleukins; Macromolecular substances; Small molecules
  • Mechanism of Action Immunostimulants; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Interleukin-15 receptor agonists; Interleukin-2 receptor beta subunit agonists; Natural killer cell stimulants; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 08 Aug 2018 Nektar Therapeutics enters into a preclinical research collaboration with Affimed Therapeutics
  • 04 Apr 2017 Pharmacodynamics data from a preclinical trial in Cancer reported at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Mar 2017 Nektar Therapeutics plans to file an IND application for NKTR 262 with the US FDA by the end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top